- Home
- PRA vs BBOT Comparison
PRA vs BBOT Comparison
Compare PRA & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRA | BBOT |
|---|---|---|
| Founded | 1976 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRA | BBOT |
|---|---|---|
| Price | $24.50 | $9.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $25.00 | $24.00 |
| AVG Volume (30 Days) | ★ 572.3K | 242.6K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.99 | N/A |
| Revenue | ★ $1,098,028,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.30 | $8.70 |
| 52 Week High | $24.77 | $14.87 |
Technical Indicators
Market Signals| Indicator | PRA | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 51.25 | 35.71 |
| Support Level | $23.88 | $8.80 |
| Resistance Level | $24.64 | $12.36 |
| Average True Range (ATR) | 0.12 | 0.56 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 28.00 | 1.63 |
Price Performance
Historical ComparisonAbout PRA ProAssurance Corporation
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.